Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O pro­grams

Lara Sul­li­van knows how em­pow­er­ing it can be for a biotech to bring in ex­per­i­men­tal drugs from Pfiz­er’s shelves. An alum of the phar­ma gi­ant’s ear­ly stage R&D port­fo­lio op­er­a­tions and strat­e­gy team, she helped spin out four or­phan dis­ease meds in­to Spring­Works Ther­a­peu­tics, which earned some sig­nif­i­cant back­ing from Bain be­fore vault­ing to a $186 mil­lion IPO with­in two years.

So when some of her old col­leagues got in touch about an an­ti­body-drug con­ju­gate pro­gram that they were shut­ter­ing — just as she was set­tling in­to her new role as CEO of Pyx­is On­col­o­gy — Sul­li­van jumped at the op­por­tu­ni­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.